MENU
+Compare
EDIT
Stock ticker: NASDAQ
AS OF
Nov 13, 04:59 PM (EDT)
Price
$2.54
Change
-$0.15 (-5.56%)
Capitalization
262.59M

EDIT Editas Medicine Forecast, Technical & Fundamental Analysis

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases... Show more

Industry: #Biotechnology
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for EDIT with price predictions
Nov 12, 2025

EDIT's Stochastic Oscillator remains in oversold zone for 12 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EDIT's RSI Oscillator exited the oversold zone, of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 244 cases, the price rose further within the following month. The odds of a continued upward trend are .

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

EDIT moved below its 50-day moving average on October 28, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EDIT crossed bearishly below the 50-day moving average on November 05, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EDIT entered a downward trend on November 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.531) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (4.933) is also within normal values, averaging (322.723).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

EDIT is expected to report earnings to fall 23.14% to -21 cents per share on February 19

Editas Medicine EDIT Stock Earnings Reports
Q4'25
Est.
$-0.22
Q3'25
Beat
by $0.02
Q2'25
Missed
by $0.23
Q1'25
Missed
by $0.36
Q4'24
Missed
by $0.22
The last earnings report on November 10 showed earnings per share of -28 cents, beating the estimate of -30 cents. With 1.07M shares outstanding, the current market capitalization sits at 262.59M.
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
265
Web
https://www.editasmedicine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MAHMF43.173.17
+7.93%
Mahindra & Mahindra Ltd.
CWBK34.80N/A
N/A
CW Bancorp
PGENY2.60N/A
N/A
Pigeon Corp.
LBNW6.09N/A
N/A
Liberty Northwest Bancorp, Inc.
OTGLY16.66-0.30
-1.77%
CD Projekt SA

EDIT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+1.50%
CRSP - EDIT
53%
Loosely correlated
-5.47%
AXON - EDIT
52%
Loosely correlated
-0.47%
PRME - EDIT
51%
Loosely correlated
-9.44%
VCYT - EDIT
49%
Loosely correlated
-0.84%
RXRX - EDIT
49%
Loosely correlated
-1.27%
More